Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 8Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Cardiotoxicity 3Triple Negative Breast Neoplasms 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Heart Failure 2Glioblastoma 2Endometrial Neoplasms 2Endometrial Hyperplasia 2Waldenstrom Macroglobulinemia 1Rectal Neoplasms 1Precancerous Conditions 1Polycystic Ovary Syndrome 1Overall Survival 1Neoplastic Cells, Circulating 1Nasopharyngeal Carcinoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1

Interventions

Control Groups 2Atorvastatin 2sacubitril and valsartan sodium hydrate drug combination 1pertuzumab 1nicotinamide-beta-riboside 1empagliflozin 1dapagliflozin 1candesartan 1Trastuzumab 1Sodium Chloride 1Simendan 1Pyruvic Acid 1Population Groups 1Ogivri 1Metoprolol 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Eplerenone 1Carvedilol 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Heart Failure × Atorvastatin × Clear all
NCT02943590 2025-05-15

STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Massachusetts General Hospital

Phase 2 Completed
300 enrolled 13 charts

Heart Failure

NCT03186404 2022-02-08

SPARE-HF

University Health Network, Toronto

Phase 2 Unknown
112 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡